Disclosing Drug Development Failures Would Aid Regulatory Science, FDA’s Hamburg Says
FDA is making the case for increased data-sharing and disclosure about drug development failures in the name of bolstering regulatory science.
FDA is making the case for increased data-sharing and disclosure about drug development failures in the name of bolstering regulatory science.